Prostate cancer

Doctor showing a model of the prostate
#Johnson & Johnson #MHRA #Prostate cancer #UK

Prostate cancer therapy gets MHRA marketing authorisation

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to a treatment for metastatic hormone-sensitive prostate cancer (mHSPC).  Akeega (niraparib and abiraterone acetate), developed by Johnson & Johnson, has been granted the authorisation as part of a combination regimen with prednisone or prednisolone and andogren deprivation therapy (ADT).  The authorisation paves the… Read More

#News #Regulatory

#Cancer drug targets #Clinical trial #DNA #Kairos Pharma #Prostate cancer #Stem cells #Tumour biology

Cancer drug resistance isn’t one problem, it’s many

Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it.  Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes durable clinical success. That problem is drug resistance. Therapies that… Read More

#Cancer Research #Exclusive Content

#Breast cancer #Clinical trial #Oncology #Ovarian cancer #Pancreatic cancer #Prostate cancer

Overcoming drug resistance with General Oncology

DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company's activities in the space. RA: Why has pancreatic cancer remained so difficult to treat? JG: Pancreatic cancer is typically diagnosed at an advanced stage, is biologically aggressive, and rapidly develops resistance to therapy. Tumours are highly heterogeneous, both between… Read More

#Exclusive Content

Colorectal cancer
#Clinical trial #Colorectal cancer #Prostate cancer

CuraCell doses first patient with TIL therapy 

Immunotherapy company CuraCell has dosed the first patients with its treatment for metastatic colorectal and metastatic prostate cancer.  CC-38 is novel autologous Tumour-Infiltrating Lymphocyte (TIL) therapy, currently being evaluated in Phase I/IIa trial. Up to 16 patients with Stage IV colorectal and prostate cancer will be enrolled in the trial, which will assess… Read More

#News

#ABPI #Clinical trials #GLP-1 #Immune response #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Weight loss

DDW Highlights: 31 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a study found obesity could be treated in other ways than through drugs… Read More

#Podcasts

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

Prostate cancer cells
#Immune response #Prostate cancer #T cell

‘Supercharged’ T cells could improve prostate cancer treatment 

Scientists have engineered new ‘supercharged’ immune cells that could attack prostate cancer more effectively.  Researchers at UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, have engineered a new class of ‘supercharged’ T cells that are stronger, longer lasting, and… Read More

#Cancer Research #News

Prostate cancer conceptualisation
#Oncology #Prostate cancer #Texas A&M University Health Science Center

Research uncovers how prostate cancer cells resist treatment

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate cancer cells—an important process that may help explain how some tumours progress and become resistant to treatment.  The study, led by Ziying Liu, a former student in the lab of Fen… Read More

#Cancer Research #Editor's Choice #News

Doctor showing a model of the prostate
#European Commission #Johnson & Johnson #Oncology #Prostate cancer

Dual action prostate cancer drug gets expanded indication in EU

The European Commission has approved an indication extension for Akeega (niraparib and abiraterone acetate dual action tablet) with prednisone or prednisolone (AAP) in combination with androgen deprivation therapy (ADT).  The regimen is now also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and BRCA1/2 mutations (germline… Read More

#News #Regulatory

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

Female scientists conducting research on samples
#Nuclear medicine #Prostate cancer

EANM launches award for prostate cancer research 

The European Association of Nuclear Medicine (EANM) has launched an award for research in prostate cancer treatment.  The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver). … Read More

#Cancer Research #News

Male patient with doctor
#CHMP #European Commission #Johnson & Johnson #Oncology #Prostate cancer

J&J drug gets EU green light for prostate cancer

Johnson & Johnson’s Akeega (niraparib and abiraterone acetate dual action tablet) could soon be available to EU patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The recommendation is for niraparib and abiraterone acetate with prednisone… Read More

#News #Regulatory

Male patient with doctor
#Archeus Technologies #Clinical trial #Prostate cancer #Radiopharmaceuticals

First patient dosed in Phase I trial of prostate cancer drug 

The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC).  ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and,… Read More

#Cancer Research #News

Johnson & Johnson head office
#Johnson & Johnson #Mergers and acquisitions #Oncology #Prostate cancer

Oncology company Halda acquired by Johnson & Johnson

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion, payable in cash at closing, subject to customary adjustments.  Halda’s portfolio includes HLD-0915, a first-in-class, oral Regulated Induced Proximity Targeting Chimeras (RIPTAC) therapeutic, in development for metastatic castration-resistant prostate cancer (mCRPC).  HLD-0915 is an innovative bifunctional small molecule therapy designed… Read More

#Business & Investment #News

#Breast cancer #DDW Highlights podcast #Drug therapy #Gene therapy #Prostate cancer

DDW Highlights: 21 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed drug therapies could prevent hereditary diseases. Elsewhere, there were… Read More

#Podcasts